Pulmonary Edema (2026-2031) - Rising Prevalence of Cardiovascular Diseases Drives Market Growth

Pulmonary Edema (2026-2031) - Rising Prevalence of Cardiovascular Diseases Drives Market Growth Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- "Pulmonary Edema - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Pulmonary Edema Market to Reach USD 11.32 Billion by 2031 as Advanced Diagnostics and Heart Failure Care Accelerate Growth

The global pulmonary edema market is projected to grow from USD 7.41 billion in 2025 and USD 7.91 billion in 2026 to USD 11.32 billion by 2031. The market is expected to register a compound annual growth rate of 7.43% between 2026 and 2031, supported by the rising prevalence of heart failure, growing demand for rapid diagnostic solutions, and wider adoption of advanced respiratory care.

Aging Population and Heart Failure Burden Drive Market Demand

The increasing incidence of heart failure and valvular disease, particularly among older adults, remains a primary pulmonary edema market growth driver. Findings from the PORTHOS study showed that heart failure affected 16.5% of adults aged 50 and older in Portugal, with prevalence rising to 30.7% among people aged 70 and above. This expanding high-risk population is contributing to recurrent hospital admissions for pulmonary congestion and fluid overload.

New cardiovascular therapies are also strengthening the treatment environment. In July 2025, the U.S. Food and Drug Administration approved Bayer's finerenone for patients with heart failure and a left ventricular ejection fraction of 40% or higher. The approval expanded treatment access for a substantial patient population and reinforced the connection between effective heart failure management and pulmonary edema prevention.

Point-of-Care Ultrasound Improves Pulmonary Edema Diagnosis

Greater use of point-of-care lung ultrasound is transforming the diagnosis of acute pulmonary edema in emergency and critical care settings. A 2025 prospective study found that lung ultrasound produced results in a median of 10 minutes, compared with 62.5 minutes for chest X-ray. Faster imaging can help clinicians identify pulmonary congestion earlier and begin appropriate treatment without unnecessary delays.

Research has also demonstrated that combining lung ultrasound with focused cardiac ultrasound can outperform NT-proBNP testing alone when diagnosing acute left heart failure in patients aged 75 and older. AI-assisted B-line quantification is further improving imaging consistency and enabling ultrasound systems to support clinical decision-making. Additional growth opportunities are emerging from AI-enabled radiology triage, emergency department workflow integration, and the expanding use of non-invasive ventilation.

Diagnostic Overlap Remains a Clinical Challenge

Differentiating pulmonary edema from chronic obstructive pulmonary disease, pneumonia, and mixed respiratory conditions remains difficult. A 2025 study reported that 38% of patients with confirmed COPD receiving guideline-based treatment were subsequently found to have undiagnosed heart failure. Biomarker elevations and overlapping imaging findings can further complicate initial assessments.

Artificial intelligence may help address this challenge. Research published in 2025 found that an AI-assisted XGBoost model significantly improved the differentiation of acute COPD exacerbations from acute heart failure. Continued development of clinical decision-support software could reduce misdiagnosis, improve treatment selection, and strengthen pulmonary edema patient outcomes.

Cardiogenic Pulmonary Edema Maintains Market Leadership

Cardiogenic pulmonary edema accounted for 41.67% of market revenue in 2025, making it the leading disease type. Its position reflects the persistent burden of left ventricular dysfunction, valvular disease, and hypertensive emergencies among hospitalized patients. These conditions frequently require urgent intervention, respiratory support, and continuous monitoring.

Non-cardiogenic pulmonary edema is forecast to record the fastest type-based growth, with a CAGR of 9.15% through 2031. Rising awareness of sepsis-associated lung injury and other permeability-related conditions is increasing demand for specialized intensive care protocols. A 2025 review reported mortality rates of 35% to 46% among intensive care patients with acute respiratory distress syndrome, underscoring the need for improved treatment options and clinical management strategies.

North America Leads as Asia-Pacific Records Rapid Expansion

North America generated 38.03% of global pulmonary edema market revenue in 2025. The region benefits from a large heart failure population, advanced hospital infrastructure, broad adoption of branded therapies, and strong access to imaging and biomarker-based diagnostics. Approximately 6.7 million U.S. adults aged 20 and older were living with heart failure in 2025, with that figure projected to reach 8.5 million by 2030. Efforts to reduce costly hospital admissions are also increasing interest in home monitoring and outpatient congestion management.

Europe remains an important market due to established acute heart failure pathways, respiratory support capabilities, and biomarker-led triage. In March 2026, finerenone received European Commission approval and UK authorization for adults with heart failure and a left ventricular ejection fraction of 40% or more, expanding treatment opportunities across the region.

Asia-Pacific is expected to achieve the fastest regional growth, registering a CAGR of 9.01% through 2031. Hospital expansion, improved awareness of acute decompensated heart failure, and wider adoption of imaging-based diagnosis are supporting demand. AI-enabled radiology platforms validated across Indian clinical sites also demonstrate the potential to improve pulmonary and cardiac triage in healthcare systems facing high patient volumes and limited specialist access.

Middle East and Africa and South America are gradually strengthening their positions through investments in intensive care units, ventilators, echocardiography, and hospital modernization. Although access remains uneven outside major cities, continued infrastructure development is expected to support the long-term expansion of pulmonary edema diagnosis and treatment services.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Aging Heart Failure and Valvular Disease Burden

4.2.2 Wider Use of Point-of-Care Lung Ultrasound and BNP Triage

4.2.3 Growth in Non-Invasive Ventilation Across Emergency and Critical Care Pathways

4.2.4 Heart Failure Guideline Spillover Into Pulmonary Edema Treatment Protocols

4.2.5 AI-Enabled Radiology Triage and ED Workflow Integration

4.2.6 Rising ICU Burden From Sepsis-Triggered Permeability Edema

4.3 Market Restraints

4.3.1 Diagnostic Overlap With COPD, Pneumonia, and Mixed Etiologies

4.3.2 Safety Limits of Aggressive Diuresis and Vasodilator Use

4.3.3 Limited Disease-Specific Therapy Options for Non-Cardiogenic Edema

4.3.4 Reimbursement and Evidence Gaps for Advanced Monitoring and Novel Biologics

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

5.1 By Type

5.1.1 Cardiogenic Pulmonary Edema

5.1.2 Non-Cardiogenic Pulmonary Edema

5.1.3 High-Altitude Pulmonary Edema

5.1.4 Pulmonary Edema Due to Infection

5.2 By Treatment & Diagnosis Method

5.2.1 Treatment

5.2.1.1 Diuretics

5.2.1.2 Oxygen Therapy

5.2.1.3 Mechanical Ventilation

5.2.1.4 Pulmonary Vasodilators

5.2.2 Diagnosis Method

5.2.2.1 Chest X-Ray

5.2.2.2 Computed Tomography

5.2.2.3 Lung Ultrasound

5.2.2.4 Echocardiography

5.2.2.5 Blood Biomarkers

5.3 By End Use

5.3.1 Hospitals

5.3.2 Home Healthcare Settings

5.3.3 Ambulatory Surgical Centers

5.3.4 Specialty Clinics

5.4 By Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East & Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East & Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)

6.3.1 AbbVie Inc.

6.3.2 Argon Medical Devices, Inc.

6.3.3 AstraZeneca plc

6.3.4 Baxter International Inc.

6.3.5 Boehringer Ingelheim International GmbH

6.3.6 Bristol-Myers Squibb Company

6.3.7 Edwards Lifesciences Corporation

6.3.8 Eli Lilly and Company

6.3.9 Fresenius Kabi AG

6.3.10 GSK plc

6.3.11 Hikma Pharmaceuticals PLC

6.3.12 Johnson and Johnson

6.3.13 Lupin Ltd.

6.3.14 Merck & Co., Inc.

6.3.15 Novartis AG

6.3.16 Pfizer Inc.

6.3.17 Roche Holding AG

6.3.18 Sanofi

6.3.19 Viatris Inc.

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/xa3guy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.